Haemonetics Corporation (HAE)
The price, the headline numbers and the latest news, in one place.
Haemonetics Corporation (HAE) Stock Price, Analysis & Data
| Bid | 107.88 |
| Market Cap | 4.95B |
| Revenue (ttm) | 1.35B |
| Net Income (ttm) | 96.29M |
| 0.52 | |
| 2.07 | |
| 52.56 | |
| 18.96 | |
| P/B (ttm) | 5.91 |
| P/S (ttm) | 3.66 |
| Earnings Date | Nov 5, 2026 |
| Ask | 115.5 |
| Volume | 443,490 |
| Avg. Volume (20D) | 885,020 |
| Open | 109.24 |
| Previous Close | 108.22 |
| Day's Range | 107.01 - 109.57 |
| 52-Week Range | 47.32 - 109.57 |
| Analyst | Buy |
| Price Target | 104.5 (-3.95%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About HAE
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma c...
Financial Performance
In 2026, Haemonetics's revenue was 1.33B, a decrease of -1.97% compared to the previous year's 1.36B. Earnings were 97.31M, a decrease of -41.97%.
Financial StatementsAnalyst Forecast
According to 10 analyst ratings, the average rating for HAE stock is "Buy". The 12-month stock price forecast is 104.5, which is downside of 3.95% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
